Clinical analysis of the treatment of spinal cord injury with umbilical cord mesenchymal stem cells

Hematopoietic recovery of acute radiation syndrome by human superoxide dismutase–expressing umbilical cord mesenchymal stromal cells

“…UCMSCs have properties similar to bone marrow-derived mesenchymal stem cells (BMMSCs), including differentiation capability, but have a greater in vitro expansion potential and lower immunogenic potential [5]. UCMSCs have been safely transplanted, resulting in the amelioration of symptoms in a variety of disease models, including Parkinson's disease [6], myocardial infarction [7], acute pancreatitis [8], acute liver failure [9], spinal cord injury [10], cerebral global ischemia [11] and the clinical treatment of side effects of radiotherapy [12]. The application of UCMSCs for the rescue of acute radiation syndrome, however, has not yet been extensively examined.…”

Lipopolysaccharides Shapes the Human Wharton's Jelly-Derived Mesenchymal Stem Cellsin Vitro

“…Human Wharton's jelly derived-MSCs (hWJ-MSCs), which are isolated from umbilical cord after the removal of blood vessels [2], have biological properties that are similar to human bone marrow-derived MSCs (hBM-MSCs) and are considered an alternative to MSCs derived from adult tissues because they are more primitive, easily obtained, rapidly expanded, immunoprivileged, have strong immunosuppressive potential, and have no related ethical issues [3,4,5,6,7]. Several disease models [8,9,10] and human clinical trials [11,12] have further confirmed the therapeutic potential of hWJ-MSCs in recent years. MSCs are attracted to and migrate toward injured tissues in host [13].…”

Mesenchymal Stem Cells as a Potential Therapeutic Tool for Spinocerebellar Ataxia

“…In most patients for whom treatment was effective, motor functions, sensory functions, or both were improved along with bowel and bladder control abilities. However, minor populations experienced headache (one case) or lower back pain (one case) during the intrathecal injection, although no treatment-related adverse events occurred during a follow-up period that ranged from 3 months to 3 years [42].…”

“…Regarding neuronal diseases other than SCA, MSC therapy can improve/stabilize the course of progressive (2), tunneling nanotubules (3), gap junctions (4), and cell fusion (5) multiple sclerosis in the first year after injection, with no serious adverse effects [29]. In addition, umbilical cord MSC injections into patients with spinal cord injuries were effective in 13 of 22 patients [42]. In most patients for whom treatment was effective, motor functions, sensory functions, or both were improved along with bowel and bladder control abilities.…”